Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Evolus Inc (EOLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 376,922
  • Shares Outstanding, K 27,333
  • Annual Sales, $ 0 K
  • Annual Income, $ -46,870 K
  • 60-Month Beta 5.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.93
  • Number of Estimates 3
  • High Estimate -0.68
  • Low Estimate -1.12
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -173.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.56 +9.79%
on 06/11/19
23.38 -41.02%
on 05/15/19
-9.09 (-39.73%)
since 05/14/19
3-Month
12.56 +9.79%
on 06/11/19
29.40 -53.10%
on 04/26/19
-11.06 (-44.51%)
since 03/14/19
52-Week
10.22 +34.93%
on 12/24/18
34.49 -60.02%
on 06/20/18
-15.06 (-52.20%)
since 06/14/18

Most Recent Stories

More News
Evolus Provides Update on Nuceiva(TM) Marketing Authorization Application in Europe

Evolus, Inc. (NASDAQ: EOLS) today provided an update on the marketing authorization application (MAA) for Nuceiva(TM) in Europe that may result in the European Commission (EC) extending its final decision...

EOLS : 13.79 (-1.08%)
Evolus Accelerates Next Phase of U.S. Launch of Jeuveau(TM) with '#NEWTOX NOW' Consumer Conversion Program

Evolus, Inc. (NASDAQ: EOLS) today announced the launch of the '#NEWTOX NOW' consumer conversion program following the rapid adoption of the company's Jeuveau(TM) Experience Treatment (J.E.T.) program....

EOLS : 13.79 (-1.08%)
ALPHAEON Corporation to Pay Off $88 million of Outstanding Third-Party Debt

ALPHAEON Corporation ("ALPHAEON"), announced today that it has completed the sale of 4.0 million shares of common stock in Evolus, Inc. (NASDAQ: EOLS) ("Evolus").

EOLS : 13.79 (-1.08%)
ALPHAEON Corporation sells 4 million shares in Evolus Inc.

ALPHAEON Corporation announced today that it has agreed to sell approximately 4.0 million shares of common stock in Evolus, Inc. (NASDAQ: EOLS) in an underwritten public offering with Morgan Stanley acting...

EOLS : 13.79 (-1.08%)
MS : 42.82 (-0.30%)
Evolus Announces First Shipment of Jeuveau(TM) (prabotulinumtoxinA-xvfs) to Customers in the United States

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that with the U.S. launch of Jeuveau(TM) (prabotulinumtoxinA-xvfs),...

EOLS : 13.79 (-1.08%)
Evolus Reports First Quarter 2019 Financial Results

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March...

EOLS : 13.79 (-1.08%)
Evolus to Participate in Two Upcoming Investor Conferences

Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that members of management will be participating in...

EOLS : 13.79 (-1.08%)
Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

ACB : 7.56 (-0.13%)
ZBH : 117.45 (-1.95%)
EOLS : 13.79 (-1.08%)
NSTG : 25.94 (+1.57%)
Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

ACB : 7.56 (-0.13%)
EOLS : 13.79 (-1.08%)
NSTG : 25.94 (+1.57%)
LH : 166.39 (-0.96%)
Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

ACB : 7.56 (-0.13%)
EOLS : 13.79 (-1.08%)
CFMS : 4.56 (-1.94%)
NSTG : 25.94 (+1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade EOLS with:

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

2nd Resistance Point 14.63
1st Resistance Point 14.21
Last Price 13.79
1st Support Level 13.26
2nd Support Level 12.73

See More

52-Week High 34.49
Fibonacci 61.8% 25.22
Fibonacci 50% 22.36
Fibonacci 38.2% 19.49
Last Price 13.79
52-Week Low 10.22

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar